Novo Nordisk A/S Target of Unusually High Options Trading (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) was the recipient of unusually large options trading on Wednesday. Investors acquired 1,919 call options on the company. This is an increase of approximately 1,122% compared to the typical daily volume of 157 call options.

Institutional investors and hedge funds have recently made changes to their positions in the company. TCG Advisors LP bought a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $27,000. Camarda Financial Advisors LLC bought a new position in Novo Nordisk A/S during the 1st quarter worth $28,000. Harvest Group Wealth Management LLC bought a new position in Novo Nordisk A/S during the 1st quarter worth $29,000. Bruderman Asset Management LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth $29,000. Finally, WP Advisors LLC bought a new position in Novo Nordisk A/S during the 1st quarter worth $39,000. Institutional investors own 7.15% of the company’s stock.

NYSE NVO traded up $0.18 on Friday, hitting $51.04. 615,113 shares of the company’s stock were exchanged, compared to its average volume of 1,524,729. The business has a 50-day moving average price of $49.20. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 0.07. Novo Nordisk A/S has a 52 week low of $41.23 and a 52 week high of $52.83. The company has a market cap of $124.60 billion, a PE ratio of 20.25, a price-to-earnings-growth ratio of 2.30 and a beta of 0.58.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Friday, May 3rd. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.04. Novo Nordisk A/S had a return on equity of 78.28% and a net margin of 33.60%. The firm had revenue of $4.46 billion during the quarter, compared to analysts’ expectations of $4.35 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 2.43 EPS for the current year.

A number of equities analysts have weighed in on NVO shares. Pareto Securities downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Credit Suisse Group raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research report on Monday, April 29th. Barclays raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 target price on the stock in a research report on Tuesday, June 11th. Deutsche Bank downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 target price on the stock. in a research report on Thursday, June 20th. Finally, UBS Group reaffirmed a “buy” rating and issued a $355.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, June 19th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $112.78.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Read More: What are the FAANG Stocks?

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.